NCT05644353View on ClinicalTrials.gov

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions
Healthy
Interventions
DRUG

Mirikizumab

Administered SC.

Trial Locations (6)

32117

LabCorp CRU, Inc., Daytona Beach

33014

Clinical Pharmacology of Miami, Miami

33143

Qps-Mra, Llc, Miami

56529

Axis, Dilworth

75247

Labcorp Clinical Research LP, Dallas

90630

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY